Understanding how Idiopathic Pulmonary Fibrosis changes over time
Official title: Proteomic Profiling of Idiopathic Pulmonary Fibrosis Progression Trajectory
Funded at University of Michigan at Ann Arbor · NIH-11111170 · Data updated 2026-11-12
This research aims to find markers in the blood that can help predict how Idiopathic Pulmonary Fibrosis (IPF) will progress in patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | September 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $685,748 |
| NIH project number | 5R01HL169166-03 |
| Project ID | NIH-11111170 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is relevant to patients diagnosed with Idiopathic Pulmonary Fibrosis, especially those whose blood samples contribute to large research cohorts.
✕Less likely to help
Patients without Idiopathic Pulmonary Fibrosis or those not involved in providing samples for this specific research may not directly benefit from this particular study.
What this research studies
Idiopathic Pulmonary Fibrosis (IPF) is a serious lung disease where the way it progresses can be very different for each person. This makes it hard to develop new treatments because it's difficult to tell if a drug is working. Our goal is to use advanced blood tests to look at thousands of proteins in patient samples. By using powerful computer analysis, we hope to find specific protein patterns that can predict how a patient's lung function might change over a year. This could help doctors better understand each patient's disease and guide future treatment choices.
Why it matters
Potential benefit: If successful, this work could lead to better ways to predict how IPF will progress, helping doctors make more informed treatment decisions and speeding up the development of new medications.
How similar studies have gone: While proteomic platforms are emerging, the ability to accurately predict IPF progression trajectory remains largely elusive, making this a novel and important area of investigation.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Oldham, Justin M — University of Michigan at Ann Arbor
- Study coordinator: Oldham, Justin M
Related research
Other NIH-funded projects on the same topics.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Unraveling IPF subtypes to guide prognosis and therapy
This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.
-
Novel antibody therapy to treat idiopathic pulmonary fibrosis
A small business gig is developing a targeted antibody drug (VSR-H5) to treat idiopathic pulmonary fibrosis in patients, aiming for better safety and effectiveness than current medicines.
-
Repurposing Vonoprazan as an inhaled therapy for IPF
A high-profile NIH grant is testing whether an existing drug, vonoprazan, can be inhaled to slow or reverse lung fibrosis in people with idiopathic pulmonary fibrosis (IPF).
-
Proteomic profile of IPF progression to help tailor treatments
A study will look for blood protein patterns that predict how IPF lung disease will progress in patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.